Know
Labs, Inc. (OTCQB: KNWN) a provider of diagnostic solutions,
announced today that Mark Tapsak, Ph.D. has joined the Company as Vice
President, Intellectual Property.
This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20190416005303/en/
Mark Tapsak, Ph.D. (Photo: Business Wire)
Dr. Tapsak most recently has been Professor of Chemistry and
Biochemistry and Interim Assistant Vice President and Dean of Graduate
Studies and Sponsored Research at Bloomsburg University of Pennsylvania.
In addition to Dr. Tapsak’s focus on intellectual property at Know Labs
he will work to support the product development, manufacturing and
launch of the Company’s UBAND Calorie Counter wearable and help drive
toward FDA approval of the Company’s non-invasive UBAND Continuous
Glucose Monitor.
Prior to his academic assignment Tapsak began his work with medical
devices with Medtronic, and then with Dexcom. At Dexcom,
a multi-billion dollar provider of continuous glucose monitoring (CGM)
systems, Dr. Tapsak was the 12th employee. He was involved
with inventions that are broad in scope and range from:
-
Composition of matter, manufacturing techniques for key Dexcom
membrane technology - Dexcom sensor design and geometry
- Electrochemical performance of Dexcom sensor
- Dexcom system design and function
- Dexcom biointerface design and composition of matter
As a result of Dr. Tapsak’s work, he currently holds 65 issued United
States patents, 52 of which are Dexcom assigned patents.
Phil Bosua, Know Labs CEO, stated, “We are thrilled to have Mark Tapsak
join the Know Labs team. He is a pioneer in the continuous glucose
monitoring marketplace, he understands our technology and will play a
key role to reinforcing the value of our intellectual property and our
go to market strategy.”
Upon joining Know Labs, Tapsak said, “When I first visited the Know Labs
research facility in Seattle last year I was stunned with the capacity
of the technology. I assisted with some testing which verified its
fundamental elements. I am excited to be a part of the team to bring the
technology to market. It is a broad platform that will have a
significant impact on human health diagnostics. Continuous glucose
monitoring is a special interest of mine. Know Labs UBAND will perform
that function accurately and most important, truly non-invasively.”
Neither Dr. Tapsak nor Know Labs, Inc. is affiliated with Dexcom, Inc.
About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade under the stock
symbol “KNWN.” The company’s technology directs structured light or
radio waves through a substance or material to capture a unique
molecular signature. The Company refers to these signatures as ChromaID™
and Bio-RFID™. ChromaID and Bio-RFID are used to identify, detect, or
diagnose substance markers or biomarkers that may be invisible to the
human eye. ChromaID and Bio-RFID scanner modules can be integrated into
a variety of wearable, mobile or bench-top form factors. This patented
and patent pending, award-winning technology makes it possible to
effectively conduct analyses that could only previously be performed by
invasive and/or large and expensive lab-based tests. For more
information on Know Labs, visit the company’s website at www.knowlabs.co
Safe Harbor Statement
This video at the link above and this release contains statements that
constitute forward-looking statements within the meaning of Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These statements appear in
a number of places in this release and include all statements that are
not statements of historical fact regarding the intent, belief or
current expectations of Know Labs, Inc., its directors or its officers
with respect to, among other things: (i) financing plans; (ii) trends
affecting its financial condition or results of operations; (iii) growth
strategy and operating strategy. The words may, would, will, expect,
estimate, can, believe, potential and similar expressions and variations
thereof are intended to identify forward-looking statements. Investors
are cautioned that any such forward-looking statements are not
guarantees of future performance and involve risks and uncertainties,
many of which are beyond Know Labs, Inc.’s ability to control, and
actual results may differ materially from those projected in the
forward-looking statements as a result of various factors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190416005303/en/